Daniel Hume
TG THERAPEUTICSAbout Daniel Hume
Daniel Hume (58) is an independent director of TG Therapeutics, serving since June 2015. He is Managing Partner at Kirby McInerney LLP, with legal expertise in securities regulation, structured finance, antitrust, and civil litigation; he is admitted to the New York State Bar and to federal courts including the U.S. Supreme Court. He holds a B.A. in philosophy from SUNY Albany (magna cum laude) and a J.D. from Columbia Law School (Notes Editor, Columbia Journal of Environmental Law). The Board affirmed his independence under Nasdaq rules in its April 11, 2025 review .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Stemline Therapeutics, Inc. (Nasdaq: STML) | Director | Until acquisition (prior to 2025) | Late clinical-stage biopharma governance; board service concluded upon acquisition |
| National Holdings Corporation (Nasdaq: NHLD) | Director | Until acquisition (prior to 2025) | Financial services governance; board service concluded upon acquisition |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Kirby McInerney LLP | Managing Partner | Current | Leads practice in securities regulation, structured finance, antitrust; broad litigation experience |
| Lirum Therapeutics, Inc. (private) | Director | Current | Private biopharma board member; potential information flow interlock with TGTX director Kenneth Hoberman (also a Lirum board member) |
Board Governance
- Independence: Board determined Hume is independent under Nasdaq criteria (review as of April 11, 2025) .
- Committee assignments (2024 activity counts shown):
- Audit Committee member; committee held 4 meetings in 2024 .
- Compensation Committee member; committee held 4 meetings in 2024 .
- Nominating & Corporate Governance Committee member; committee held 3 meetings in 2024 .
- Committee chairs: Audit—Laurence N. Charney (also Audit Committee financial expert); Compensation—Kenneth Hoberman; Nominating—Dr. Sagar Lonial .
- Attendance and engagement: The Board met 4 times in 2024; each incumbent director (including Hume) attended at least 75% of Board and committee meetings; all directors attended the 2024 Annual Meeting .
- Lead Independent Director: Laurence N. Charney presides at regular executive sessions of independent directors and leads CEO evaluations .
| Governance Detail | Hume Status | Citation |
|---|---|---|
| Independence | Independent | |
| Audit Committee | Member (4 meetings held) | |
| Compensation Committee | Member (4 meetings held; signatory to committee report) | |
| Nominating & Corporate Governance Committee | Member (3 meetings held) | |
| Board attendance | ≥75% of Board/committee meetings in 2024 |
Fixed Compensation
| Component (2024) | Description | Amount | Citation |
|---|---|---|---|
| Board cash retainer | Standard non‑employee director retainer | $70,000 | |
| Committee membership fees | Audit $10,000; Compensation $7,500; Nominating $5,000 | $22,500 total | |
| Committee chair fees | Not applicable (Hume is not a chair) | $0 | |
| Total cash paid to Hume (2024) | Fees earned or paid in cash | $95,000 |
Notes:
- TGTX maintained cash compensation levels; equity was increased to align total director compensation at the 75th percentile of the 2024 peer group .
Performance Compensation
| Equity Element | Grant Date | Shares | Grant Date Fair Value | Vesting | Citation |
|---|---|---|---|---|---|
| Annual restricted stock (2024) | 2024-06-19 | 22,250 | $373,133 | Vests on 2025-06-14 (one-year), subject to continued service | |
| Program design | Annual director equity grants generally vest on the one-year anniversary | — | — | Time-based; no performance metrics disclosed for directors |
Other Directorships & Interlocks
| Company | Role | Status | Interlock/Notes | Citation |
|---|---|---|---|---|
| Lirum Therapeutics, Inc. (private) | Director | Current | Shared board service with TGTX director Kenneth Hoberman (potential information flow interlock) | |
| Stemline Therapeutics, Inc. | Director | Former (until acquisition) | Hoberman is COO of Stemline; Hume’s board role ended upon acquisition | |
| National Holdings Corporation | Director | Former (until acquisition) | Concluded upon acquisition |
Expertise & Qualifications
- Legal and regulatory expertise across securities regulation, structured finance, antitrust, and civil litigation—supports audit and governance oversight .
- Credentials: B.A. SUNY Albany (magna cum laude), J.D. Columbia Law School; admitted to NY Bar and U.S. Supreme Court—strong compliance orientation .
- Prior public company board experience in biopharma and financial services—enhances board effectiveness .
Equity Ownership
| Ownership Detail (as of 2025-04-14) | Amount | % of Shares Outstanding | Citation |
|---|---|---|---|
| Total beneficial ownership (shares) | 178,030 | <1% | |
| Unvested restricted stock awards (aggregate, as of 2024-12-31) | 120,982 | — | |
| Stock options | None reported for non‑employee directors | — | |
| Hedging/pledging | Hedging prohibited by Insider Trading Policy; no pledging disclosed | — |
Governance Assessment
- Strengths:
- Independent director serving on all three key committees (Audit, Compensation, Nominating), indicating high engagement and influence on governance processes .
- Adequate attendance (≥75%) and participation across Board/committee meetings; attendance at annual meeting supports investor-facing engagement .
- Legal/regulatory background and Supreme Court admission enhance oversight quality and risk management, particularly on Audit and governance matters .
- Equity alignment via annual restricted stock grants; company prohibits hedging; director equity increased to peer group 75th percentile to strengthen alignment .
- Watch items / potential conflicts:
- Interlock: Shared service with TGTX director Kenneth Hoberman on Lirum Therapeutics’ board; no related‑party transactions disclosed with Lirum, but monitor for any future dealings that could create conflicts .
- No related‑person transactions or compensation committee interlocks requiring disclosure for Hume; committee independence affirmed—low conflict risk currently .
- Investor sentiment signals:
- 2024 say‑on‑pay approval was 57.7% (modest support), highlighting broader scrutiny of executive pay structures; while this is aimed at NEO compensation, it can influence board oversight expectations .
- Overall: Governance quality appears solid with independence, committee breadth, and attendance. No disclosed red flags for Hume; maintain surveillance on private board interlocks and any evolving related‑party exposures .